Mannucci P M
Angelo Bianchi Bonomi Hemophilia, Thrombosis Center, Department of Medicine and Medical Specialties, University of Milan and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy.
J Thromb Haemost. 2007 Jul;5 Suppl 1:68-72. doi: 10.1111/j.1538-7836.2007.02463.x.
The rapidly developing countries of Asia are witnessing substantial progress in the awareness of bleeding and thrombotic disorders as important health care problems. It has been thought for a long time that venous thromboembolism is very rare in Asia. Recent large studies that involved the majority of Asian countries demonstrated that this is not true, so that the practice of not using thromboprophylaxis in high-risk medical and surgical cases should be abandoned. The management of hemophilia and allied coagulation disorders has also dramatically improved in several Asian countries, due to the increased availability of blood products for replacement therapy coupled with the leadership role exerted by a few charismatic physicians, particularly in India and Thailand. As to the future, countries such as China and India have the capacity and expertise in biotechnology to consider the production of recombinant factors and gene transfer as the best strategies to tackle the management of persons with hemophilia in these densely populated and huge countries.
亚洲快速发展的国家正在见证人们对出血和血栓形成性疾病作为重要医疗保健问题的认识取得重大进展。长期以来,人们一直认为静脉血栓栓塞在亚洲非常罕见。最近涉及大多数亚洲国家的大型研究表明并非如此,因此,在高风险医疗和外科病例中不使用血栓预防措施的做法应该摒弃。由于用于替代疗法的血液制品供应增加,再加上一些有魅力的医生发挥的引领作用,尤其是在印度和泰国,血友病及相关凝血障碍的管理在几个亚洲国家也有了显著改善。至于未来,中国和印度等国家在生物技术方面有能力和专业知识,可考虑将生产重组因子和基因转移作为解决这些人口密集大国中血友病患者管理问题的最佳策略。